NURS617 EXAM 1 Actual Exam 2026/2027 Complete
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS (Questions 1-15)
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin therapy. The NP
understands that warfarin's anticoagulant effect is monitored using which laboratory value, and
what is the therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0. [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to monitor warfarin.
Q2: A patient taking carbamazepine for epilepsy is started on oral contraceptives. The NP
recognizes that carbamazepine may reduce contraceptive efficacy due to which pharmacokinetic
mechanism?
A. Inhibition of CYP3A4 enzymes
B. Induction of CYP3A4 enzymes. [CORRECT]
C. Inhibition of P-glycoprotein efflux pumps
D. Increased protein binding of estrogen
Correct Answer: B
Rationale: Carbamazepine is a potent CYP450 enzyme inducer, specifically inducing CYP3A4
(B). This increases the metabolism of oral contraceptives (which are CYP3A4 substrates),
reducing their efficacy and increasing risk of unintended pregnancy. Inhibition (A) would
increase drug levels. P-glycoprotein (C) and protein binding (D) are not the primary
mechanisms.
,Q3: A 45-year-old patient with chronic pain is prescribed codeine for post-operative pain
management. The patient reports no pain relief. Genetic testing reveals the patient is a CYP2D6
poor metabolizer. The NP understands that:
A. Codeine is a prodrug requiring CYP2D6 conversion to morphine for analgesic effect.
[CORRECT]
B. Codeine directly binds to mu-opioid receptors without metabolism
C. The patient should receive a higher dose of codeine
D. CYP2D6 poor metabolizers experience enhanced codeine toxicity
Correct Answer: A
Rationale: Codeine is a prodrug that requires metabolism by CYP2D6 to convert approximately
10% of the dose into morphine, which provides the analgesic effect (A). Poor metabolizers
cannot effectively convert codeine to morphine, resulting in inadequate pain relief. The patient
should be switched to morphine or another opioid not requiring CYP2D6 metabolism.
Q4: A patient with G6PD deficiency develops acute hemolytic anemia after receiving
primaquine for malaria prophylaxis. The NP recognizes this adverse reaction is an example of:
A. Type A (augmented) pharmacological reaction
B. Type B (bizarre) idiosyncratic reaction related to pharmacogenomics. [CORRECT]
C. Type C (chronic) reaction from cumulative dosing
D. Type D (delayed) carcinogenic reaction
Correct Answer: B
Rationale: G6PD deficiency is an X-linked genetic disorder affecting approximately 400 million
people worldwide. Hemolytic anemia with oxidant drugs like primaquine represents a Type B
(bizarre) reaction that is unpredictable, not dose-related, and occurs in genetically susceptible
individuals (B). This is a pharmacogenomic consideration requiring testing before prescribing
certain medications.
Q5: A patient with renal failure requires dosing adjustment for a medication primarily eliminated
by glomerular filtration. The NP understands that which factor is LEAST likely to affect
glomerular filtration rate (GFR)?
A. Age-related decrease in nephron number
B. Nonsteroidal anti-inflammatory drug use
,C. Plasma protein binding of the drug. [CORRECT]
D. Dehydration status
Correct Answer: C
Rationale: Glomerular filtration is a passive process dependent on hydrostatic and oncotic
pressure gradients, renal blood flow, and functional nephron mass. Plasma protein binding (C)
primarily affects drug distribution and tubular secretion/reabsorption, not GFR itself. Age (A),
NSAIDs affecting renal perfusion (B), and hydration status (D) all directly impact GFR.
Q6: A patient receiving digoxin develops toxicity manifested by nausea, vomiting, and
ventricular arrhythmias. The serum digoxin level is 3.2 ng/mL. The NP understands that the
therapeutic index of digoxin is:
A. Wide, allowing for safe dosing without monitoring
B. Narrow, with therapeutic range 0.5-2.0 ng/mL. [CORRECT]
C. Moderate, with therapeutic range 2.0-4.0 ng/mL
D. Variable depending on patient age
Correct Answer: B
Rationale: Digoxin has a narrow therapeutic index (NTI), with a therapeutic range of 0.5-2.0
ng/mL (B). Levels above 2.0 ng/mL increase risk of toxicity, while levels below 0.5 ng/mL may
be subtherapeutic. The patient's level of 3.2 ng/mL explains the toxicity symptoms. NTI drugs
require careful monitoring and precise dosing.
Q7: A patient taking ketoconazole for fungal infection is prescribed simvastatin 80 mg daily for
hyperlipidemia. The NP should be most concerned about:
A. Increased risk of myopathy and rhabdomyolysis. [CORRECT]
B. Decreased efficacy of ketoconazole
C. Enhanced hypoglycemic effects
D. Reduced anticoagulant effect of warfarin
Correct Answer: A
Rationale: Ketoconazole is a potent CYP3A4 inhibitor. Simvastatin is metabolized by CYP3A4;
concurrent use with strong inhibitors increases simvastatin levels, significantly increasing risk of
myopathy and rhabdomyolysis (A). The FDA recommends avoiding simvastatin doses above 20
mg with strong CYP3A4 inhibitors. Alternative statins (pravastatin, rosuvastatin) not
metabolized by CYP3A4 should be considered.
, Q8: A patient with liver cirrhosis is prescribed lorazepam instead of diazepam for anxiety. The
NP understands this choice is based on which pharmacokinetic principle?
A. Lorazepam undergoes Phase II glucuronidation rather than Phase I oxidation. [CORRECT]
B. Lorazepam has higher protein binding in cirrhosis
C. Diazepam is renally eliminated
D. Lorazepam has active metabolites that are safer
Correct Answer: A
Rationale: In liver disease, Phase I oxidation (CYP450-mediated) is impaired earlier and more
severely than Phase II conjugation. Lorazepam undergoes glucuronidation (Phase II), while
diazepam undergoes oxidation (Phase I) producing active metabolites that accumulate in liver
disease (A). This makes lorazepam safer in patients with hepatic impairment.
Q9: A patient on chronic phenytoin therapy for seizures requires increased doses of warfarin to
maintain therapeutic INR. This interaction occurs because phenytoin:
A. Inhibits CYP2C9, reducing warfarin metabolism
B. Induces CYP2C9 and CYP3A4, increasing warfarin metabolism. [CORRECT]
C. Displaces warfarin from albumin binding sites
D. Inhibits vitamin K absorption
Correct Answer: B
Rationale: Phenytoin is a potent enzyme inducer affecting multiple CYP450 enzymes including
CYP2C9 and CYP3A4 (the primary enzymes metabolizing S-warfarin and R-warfarin,
respectively). This increases warfarin clearance, requiring higher doses to maintain therapeutic
INR (B). When phenytoin is discontinued, warfarin levels increase, risking hemorrhage.
Q10: A patient receives a loading dose of amiodarone for ventricular tachycardia. The NP
understands the rationale for a loading dose is based on which pharmacokinetic parameter?
A. Long elimination half-life requiring weeks to reach steady state. [CORRECT]
B. High volume of distribution requiring rapid saturation
C. Extensive first-pass metabolism
D. Low bioavailability requiring higher initial doses
Correct Answer: A
Rationale: Amiodarone has an exceptionally long elimination half-life (40-55 days) due to
extensive lipophilic tissue distribution. Without a loading dose, therapeutic plasma
Questions and Verified Answers with Detailed
Rationales Pharmacotherapeutics Review Grade A
100% Correct Pass Guaranteed - A+ Graded
SECTION 1: PHARMACOKINETICS AND PHARMACODYNAMICS (Questions 1-15)
Q1: A 68-year-old patient with atrial fibrillation is started on warfarin therapy. The NP
understands that warfarin's anticoagulant effect is monitored using which laboratory value, and
what is the therapeutic range for most indications?
A. aPTT; 1.5-2.5 times control
B. INR; 2.0-3.0. [CORRECT]
C. Anti-Xa; 0.5-1.0 IU/mL
D. Bleeding time; 3-9 minutes
Correct Answer: B
Rationale: Warfarin's anticoagulant effect is monitored using the International Normalized Ratio
(INR). For most indications, including atrial fibrillation and venous thromboembolism, the
therapeutic target INR is 2.0-3.0 (B). aPTT (A) is used to monitor unfractionated heparin. Anti-
Xa (C) is used to monitor LMWH. Bleeding time (D) is not used to monitor warfarin.
Q2: A patient taking carbamazepine for epilepsy is started on oral contraceptives. The NP
recognizes that carbamazepine may reduce contraceptive efficacy due to which pharmacokinetic
mechanism?
A. Inhibition of CYP3A4 enzymes
B. Induction of CYP3A4 enzymes. [CORRECT]
C. Inhibition of P-glycoprotein efflux pumps
D. Increased protein binding of estrogen
Correct Answer: B
Rationale: Carbamazepine is a potent CYP450 enzyme inducer, specifically inducing CYP3A4
(B). This increases the metabolism of oral contraceptives (which are CYP3A4 substrates),
reducing their efficacy and increasing risk of unintended pregnancy. Inhibition (A) would
increase drug levels. P-glycoprotein (C) and protein binding (D) are not the primary
mechanisms.
,Q3: A 45-year-old patient with chronic pain is prescribed codeine for post-operative pain
management. The patient reports no pain relief. Genetic testing reveals the patient is a CYP2D6
poor metabolizer. The NP understands that:
A. Codeine is a prodrug requiring CYP2D6 conversion to morphine for analgesic effect.
[CORRECT]
B. Codeine directly binds to mu-opioid receptors without metabolism
C. The patient should receive a higher dose of codeine
D. CYP2D6 poor metabolizers experience enhanced codeine toxicity
Correct Answer: A
Rationale: Codeine is a prodrug that requires metabolism by CYP2D6 to convert approximately
10% of the dose into morphine, which provides the analgesic effect (A). Poor metabolizers
cannot effectively convert codeine to morphine, resulting in inadequate pain relief. The patient
should be switched to morphine or another opioid not requiring CYP2D6 metabolism.
Q4: A patient with G6PD deficiency develops acute hemolytic anemia after receiving
primaquine for malaria prophylaxis. The NP recognizes this adverse reaction is an example of:
A. Type A (augmented) pharmacological reaction
B. Type B (bizarre) idiosyncratic reaction related to pharmacogenomics. [CORRECT]
C. Type C (chronic) reaction from cumulative dosing
D. Type D (delayed) carcinogenic reaction
Correct Answer: B
Rationale: G6PD deficiency is an X-linked genetic disorder affecting approximately 400 million
people worldwide. Hemolytic anemia with oxidant drugs like primaquine represents a Type B
(bizarre) reaction that is unpredictable, not dose-related, and occurs in genetically susceptible
individuals (B). This is a pharmacogenomic consideration requiring testing before prescribing
certain medications.
Q5: A patient with renal failure requires dosing adjustment for a medication primarily eliminated
by glomerular filtration. The NP understands that which factor is LEAST likely to affect
glomerular filtration rate (GFR)?
A. Age-related decrease in nephron number
B. Nonsteroidal anti-inflammatory drug use
,C. Plasma protein binding of the drug. [CORRECT]
D. Dehydration status
Correct Answer: C
Rationale: Glomerular filtration is a passive process dependent on hydrostatic and oncotic
pressure gradients, renal blood flow, and functional nephron mass. Plasma protein binding (C)
primarily affects drug distribution and tubular secretion/reabsorption, not GFR itself. Age (A),
NSAIDs affecting renal perfusion (B), and hydration status (D) all directly impact GFR.
Q6: A patient receiving digoxin develops toxicity manifested by nausea, vomiting, and
ventricular arrhythmias. The serum digoxin level is 3.2 ng/mL. The NP understands that the
therapeutic index of digoxin is:
A. Wide, allowing for safe dosing without monitoring
B. Narrow, with therapeutic range 0.5-2.0 ng/mL. [CORRECT]
C. Moderate, with therapeutic range 2.0-4.0 ng/mL
D. Variable depending on patient age
Correct Answer: B
Rationale: Digoxin has a narrow therapeutic index (NTI), with a therapeutic range of 0.5-2.0
ng/mL (B). Levels above 2.0 ng/mL increase risk of toxicity, while levels below 0.5 ng/mL may
be subtherapeutic. The patient's level of 3.2 ng/mL explains the toxicity symptoms. NTI drugs
require careful monitoring and precise dosing.
Q7: A patient taking ketoconazole for fungal infection is prescribed simvastatin 80 mg daily for
hyperlipidemia. The NP should be most concerned about:
A. Increased risk of myopathy and rhabdomyolysis. [CORRECT]
B. Decreased efficacy of ketoconazole
C. Enhanced hypoglycemic effects
D. Reduced anticoagulant effect of warfarin
Correct Answer: A
Rationale: Ketoconazole is a potent CYP3A4 inhibitor. Simvastatin is metabolized by CYP3A4;
concurrent use with strong inhibitors increases simvastatin levels, significantly increasing risk of
myopathy and rhabdomyolysis (A). The FDA recommends avoiding simvastatin doses above 20
mg with strong CYP3A4 inhibitors. Alternative statins (pravastatin, rosuvastatin) not
metabolized by CYP3A4 should be considered.
, Q8: A patient with liver cirrhosis is prescribed lorazepam instead of diazepam for anxiety. The
NP understands this choice is based on which pharmacokinetic principle?
A. Lorazepam undergoes Phase II glucuronidation rather than Phase I oxidation. [CORRECT]
B. Lorazepam has higher protein binding in cirrhosis
C. Diazepam is renally eliminated
D. Lorazepam has active metabolites that are safer
Correct Answer: A
Rationale: In liver disease, Phase I oxidation (CYP450-mediated) is impaired earlier and more
severely than Phase II conjugation. Lorazepam undergoes glucuronidation (Phase II), while
diazepam undergoes oxidation (Phase I) producing active metabolites that accumulate in liver
disease (A). This makes lorazepam safer in patients with hepatic impairment.
Q9: A patient on chronic phenytoin therapy for seizures requires increased doses of warfarin to
maintain therapeutic INR. This interaction occurs because phenytoin:
A. Inhibits CYP2C9, reducing warfarin metabolism
B. Induces CYP2C9 and CYP3A4, increasing warfarin metabolism. [CORRECT]
C. Displaces warfarin from albumin binding sites
D. Inhibits vitamin K absorption
Correct Answer: B
Rationale: Phenytoin is a potent enzyme inducer affecting multiple CYP450 enzymes including
CYP2C9 and CYP3A4 (the primary enzymes metabolizing S-warfarin and R-warfarin,
respectively). This increases warfarin clearance, requiring higher doses to maintain therapeutic
INR (B). When phenytoin is discontinued, warfarin levels increase, risking hemorrhage.
Q10: A patient receives a loading dose of amiodarone for ventricular tachycardia. The NP
understands the rationale for a loading dose is based on which pharmacokinetic parameter?
A. Long elimination half-life requiring weeks to reach steady state. [CORRECT]
B. High volume of distribution requiring rapid saturation
C. Extensive first-pass metabolism
D. Low bioavailability requiring higher initial doses
Correct Answer: A
Rationale: Amiodarone has an exceptionally long elimination half-life (40-55 days) due to
extensive lipophilic tissue distribution. Without a loading dose, therapeutic plasma
